|
GLSI | Greenwich Lifesciences, Inc. |
|
|
GLSI | Greenwich Lifesciences, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.01 |
| Leverage | 42.61% |
| Market Cap | $ 269.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -19.4m |
| Margin | 0.00% |
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.